Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone

Sai Li
Peking Union Medical College

Et al.

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Bacterial Infections and Mycoses Commons, Genetics Commons, and the Immunology of Infectious Disease Commons

Repository Citation
Li S, Su X, Le W, Jiang F, Wang B, Rice PA. (2014). Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone. Open Access Publications by UMMS Authors. https://doi.org/10.1186/s12879-014-0622-0. Retrieved from https://escholarship.umassmed.edu/oapubs/2507

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011–2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone

Sai Li1, Xiao-Hong Su1*, Wen-Jing Le1, Fa-Xing Jiang2, Bao-Xi Wang1 and Peter A Rice3

Abstract

Background: Evolving gonococcal antimicrobial resistance (AMR) poses a serious threat to public health. The aim of this study was to: update antimicrobial susceptibility data of Neisseria gonorrhoeae recently isolated in Nanjing, China and identify specific determinants of antimicrobial resistance and genotypes of isolates with decreased sensitivity to ceftriaxone.

Methods: 334 N. gonorrhoeae isolates were collected consecutively from symptomatic men attending the Nanjing STD Clinic between April 2011 and December 2012. The minimum inhibitory concentrations (MICs) for penicillin, tetracycline, ciprofloxacin, spectinomycin and ceftriaxone were determined by agar plate dilution for each isolate. Penicillinase-producing N. gonorrhoeae (PPNG) and tetracycline-resistant N. gonorrhoeae (TRNG) were examined and typed for β-lactamase and tetM encoding plasmids respectively. Isolates that displayed elevated MICs to ceftriaxone (MIC ≥0.125 mg/L) were also tested for mutations in penA, mtrR, porB1b, ponA and pilQ genes and characterized by Neisseria gonorrhoeae multi-antigen sequence typing (NG-MAST).

Results: 98.8% (330/334) of N. gonorrhoeae isolates were resistant to ciprofloxacin; 97.9% (327/334) to tetracycline and 67.7% (226/334) to penicillin. All isolates were susceptible to ceftriaxone (MIC ≤0.25 mg/L) and spectinomycin (MIC ≤32 mg/L). Plasmid mediated resistance was exhibited by 175/334 (52%) of isolates: 120/334 (36%) of isolates were PPNG and 104/334 (31%) were TRNG. 90.0% (108/120) of PPNG isolates carried the Asia type β-lactamase encoding plasmid and 96% (100/104) of TRNG isolates carried the Dutch type tetM containing plasmid. Elevated MICs for ceftriaxone were present in 15 (4.5%) isolates; multiple mutations were found in penA, mtrR, porB1b and ponA genes. The 15 isolates were distributed into diverse NG-MAST sequence types; four different non-mosaic penA alleles were identified, including one new type.

Conclusions: N. gonorrhoeae isolates in Nanjing generally retained similar antimicrobial resistance patterns to isolates obtained five years ago. Fluctuations in resistance plasmid profiles imply that genetic exchange among gonococcal strains is ongoing and is frequent. Ceftriaxone and spectinomycin remain treatments of choice of gonorrhea in Nanjing, however, decreased susceptibility to ceftriaxone and rising MICs for spectinomycin of N. gonorrhoeae isolates underscore the importance of maintaining surveillance for AMR (both phenotypic and genotypic).

Keywords: Neisseria gonorrhoeae, Antimicrobial resistance, Resistance plasmids, Ceftriaxone, Resistance determinants
**Background**

Gonorrhea is the fifth most commonly reported infectious disease in China; nearly 100,000 cases were reported officially nationwide in 2013 [1]. Worldwide, over 106 million new infections are diagnosed annually [2]. Effective treatment is key in preventing complications and controlling transmission of *N. gonorrhoeae*. Unfortunately, this bacterium has developed resistance to antimicrobials (AMR) including sulfonamides, penicillins, tetracyclines and quinolones [3,4]. In recent years treatment failures have occurred when extended-spectrum cephalosporins (ESCs), the most widely used agents for treatment of gonorrhea, were used, and associated increases in AMR to ESCs have been reported in several countries [5-11]. The molecular mechanisms associated with reduced susceptibility or resistance to ESCs include mutations in several gene loci; penA [12-16], mtrR [17,18], penB [17,19], ponA [6,20] and pilQ [21,22] and their multifaceted interactions [6,23].

Several public health organizations have published their action/response plans to control the spread and impact of ESCs-resistant gonococci [2,4,25]. These have stressed the importance of enhancing quality-assured surveillance of gonococcal AMR both locally and internationally, with a focus on ESCs.

In China, the surveillance of *N. gonorrhoeae* AMR is conducted by the National Center for Sexually Transmitted Diseases (STDs) Control, China CDC, which systematically collects *N. gonorrhoeae* AMR data from 10~16 geographically separate monitoring sentinels and provides external quality assessment. Annual AMR rates are available in brief reports issued by China CDC (1987-current) [26] and are also published by the World Health Organization (WHO), Western Pacific Region Gonococcal Antimicrobial Surveillance Programme (1992–current) [27-29].

During 2011–2012, the period of this investigation, ceftriaxone and spectinomycin were the only antimicrobials recommended officially in the Chinese guidelines for the treatment of gonorrhea [30], however, a wide variety of antimicrobials including (fluoro) quinolones were prescribed unofficially outside of STD Clinics and purchased over the counter to treat gonorrhea.

The Nanjing STD clinic, operating as a sentinel site in Eastern China, performs AMR tests routinely on 10%–20% of gonococcal isolates recovered in this city. We performed this study in 2011–12, to assess the impact, in Nanjing, of recent changes in ceftriaxone susceptibility of *N. gonorrhoeae* that have been reported [31-34] and to characterize genetic determinants and NG-MAST sequence types (STs) of isolates with decreased sensitivity to ceftriaxone.

**Methods**

**Subjects and bacterial strains**

*N. gonorrhoeae* isolates were isolated from male adults with symptoms/signs of urethritis (confirmed by ≥5 polymorphonuclear neutrophils [PMNs]/oil immersion microscopic field seen in all urethral specimens) in the STD clinic of the National Center for STD Control in Nanjing, China between April 2011 and December 2012. These isolates represented 18.1% of the reported gonorrhea cases in Nanjing during this period. Epidemiological data was acquired by interviews conducted by clinical staff using standardized data recording instruments. Isolates from all but 2 men were from ethnic Han (332/334) and 99.4% (332/334) of men were heterosexual. The mean (± SEM) age was 36.7 ± 3.3 years, the median, 36 (range: 19 to 65), there being no significant difference (p > 0.05) compared with the national average age of gonorrhea cases in men (mean [± SEM], 34.9 ± 3.2). 61.3% of men were married. Approval to enroll human subjects was given by the Institutional Review Board of the Institute of Dermatology, Chinese Academy of Medical Science. The study was introduced and explained to potential subjects who voluntarily gave written and signed consent. Urethral specimens were collected with cotton swabs and immediately streaked onto Thayer-Martin (T-M) selective medium. Inoculated plates were incubated at 36°C in candle jars for 24–48 h. *N. gonorrhoeae* was identified by colonial morphology, Gram’s stain, and oxidase testing, which are sufficient to identify *N. gonorrhoeae* colonies isolated on selective medium, particularly for samples from the urethral tracts of symptomatic men [35,36]. Isolates were subcultured onto GC agar base (Difco, Detroit, MI) supplemented with 1% IsovitaleX™ (Oxoid, USA) and pure cultures swabbed, suspended in tryptone-based soy broth and frozen (−70°C) until used for antimicrobial testing.

**Antimicrobial susceptibility testing**

The minimum inhibitory concentrations (MICs; mg/L) of *N. gonorrhoeae* to penicillin, tetracycline, ciprofloxacin, spectinomycin and ceftriaxone were determined by the agar dilution method (Clinical Laboratory Standards Institute [37]), using 2-fold serial dilutions of antibiotics (all purchased from Sigma Aldrich, Saint Louis, MO, USA): penicillin 0.125–8 mg/L, tetracycline 0.25–16 mg/L, ciprofloxacin 0.25–8 mg/L, spectinomycin 4–128 mg/L and ceftriaxone 0.004–0.5 mg/L. WHO reference strains A, G, I and J (kindly provided by Dr. J. W. Tapsall, Prince of Wales Hospital, Sydney, Australia) and a ceftriaxone-resistant strain (kindly provided by Carmen Ardanuy, L’Hospitalet de Llobregat, Barcelona, Spain [38]) were used as controls. In addition, we included, as controls, two strains isolated from our prior study that had diminished susceptibility to ceftriaxone (MIC = 0.125 and 0.25 mg/L) [39]. MIC breakpoints for assigning susceptibility, intermediate and resistance status to *N. gonorrhoeae* isolates were determined according to Clinical and Laboratory Standards Institute (CLSI) Document M07-A9 (M100-S22) [37].
Production of β-lactamase was identified by paper acidometric test (phenotype method) [39,40]. Resistance patterns were defined as follows [41]:

- **PPNG** (Penicillinase-producing *N. gonorrhoeae*), β-lactamase positive
- **TRNG** (Plasmid-mediated tetracycline-resistant *N. gonorrhoeae*), MIC to tetracycline ≥16 mg/L, also confirmed by PCR-based genotyping
- **PPNG/TRNG**, β-lactamase positive and MIC to tetracycline ≥16 mg/L
- **PenR** (chromosomally mediated resistance to penicillin), non-PPNG, non-TRNG, MIC to penicillin ≥2 mg/L and MIC to tetracycline <2 mg/L
- **TetR** (chromosomally mediated resistance to tetracycline), non-PPNG, non-TRNG, MIC to tetracycline ≥2 mg/L and MIC to penicillin <2 mg/L
- **CMRNG** (chromosomal resistance to penicillin and tetracycline), non-PPNG, non-TRNG, MIC to penicillin ≥2 mg/L and MIC to tetracycline ≥2 mg/L.

**Identification and typing of tetM and β-lactamase gene producing plasmids**

Bacterial DNA was extracted according to a published method [39]. For *tetM* gene containing plasmids, PCR reactions were performed using a universal forward primer; 5′-825CTCG AACAAGAGGAAAGC-3′ and reverse primers 5′-1602GC ATTCCACTTCCCAAC-3′ to identify the presence of the “American” type *tetM* plasmid and 5′-1267TGCAGC AGAGGGAGG1253 to identify the “Dutch” type. PCR products were separated by agarose electrophoresis, stained with ethidium bromide and visualized using ultraviolet fluorescent light for the presence of a 778 bp fragment (“American”) or a 443 bp fragment (“Dutch”) [42]. An American type *tetM* containing strain identified in our previously study [39] and WHO reference strain G (Dutch type) were used as positive controls.

β-lactamase producing plasmids were characterized using multiplex PCR (employing specific forward and reverse primers [43]) followed by electrophoresis to identify specifically sized PCR products, thereby differentiating three common plasmids: Asian (958 bp), African (1191 bp) and Toronto (650 bp). Positive control PCR products derived from plasmids pJG4 (Asian type), pJD5 (African type) and pJD7 (Toronto type) (provided by J.R. Dillon, University of Saskatchewan, Canada) were included in each assay.

**Sequencing of N. gonorrhoeae genetic determinants associated with decreased susceptibility to ceftriaxone**

Amplification of *penA*, *mtrR*, *porB* (and also *ponA* and *pitQ*) was performed using published primers and conditions [44,45]. PCR products were sequenced twice bidirectionally on an Applied Biosystems 3730XL DNA automatic sequencer. Nucleotide and deduced amino acid sequences were edited and aligned against their respective prototypes [44]. A newly identified PBP2 type was designated XLI according to previously used nomenclature [12,15,46–49].

**Molecular epidemiological typing**

*N. gonorrhoeae* multiantigen sequence typing (NG-MAST) was performed by PCR amplification and sequencing of two high polymorphic fragments in *porB* and *thpB* genes according to previously described methods [50]. Allele numbers and sequence type numbers were assigned through the NG-MAST database (http://www.ng-mast.net).

**Nucleotide sequence accession numbers**

*porB* sequences were submitted to the GenBank nucleotide database under accession numbers [Genbank: KF660589-KF660594] and [Genbank: KF668353- KF668360]. Novel *penA* nucleotide sequences associated with reduced susceptibility to ESCs identified in this study were deposited in the GenBank database under accession number [Genbank: KF676657].

**Statistical analysis**

The Chi-Square test (2-tailed) was used to assess significance of associations and compare resistance rates; p values <0.05 were considered significant. Statistical analyses were performed using IBM SPSS Statistics version 22.0.

**Results**

**Antimicrobial susceptibilities**

Among 652 consecutively enrolled male subjects with urethritis, 340 (52.1%) were infected with *N. gonorrhoeae*; antimicrobial susceptibility testing of 334 successfully retrieved isolates is summarized in Table 1 (six isolates were not recovered from storage or could not be separated from contaminants). Resistance rates to antibiotics formerly or now recommended for treatment of gonorrhea in China were: ciprofloxacin 98.8%, tetracycline 97.9%, penicillin 67.7%, all isolates were susceptible to spectinomycin and ceftriaxone. The minimum inhibitory concentration of 50% and 90% of gonococcal isolates (MIC50/MIC90) for ciprofloxacin, tetracycline, penicillin, spectinomycin and ceftriaxone were >8/>8, 8/>16, 2/>8, 16/32 and 0.03/0.06 mg/L, respectively.

**Penicillin and tetracycline resistance phenotypes**

Penicillin and tetracycline resistance phenotypes were categorized based on plasmid or chromosomally mediated resistance mechanisms. Overall, plasmid mediated resistance to either penicillin or tetracycline was exhibited by 175/334 (52%): 71/334 (21%) of isolates were...
PPNG exclusively; 55/334 (16%) were TRNG exclusively and 49 (15%) were PPNG/TRNG. CMRNG or TetR alone was identified in 27.8% and 18.3% of isolates, respectively. PenR alone was not detected.

Molecular typing of PPNG and TRNG
120 β-lactamase producing *N. gonorrhoeae* isolates were distributed into two plasmid types: Asian and African. No Toronto plasmid was detected. 108 (90%) isolates contained the Asian plasmid and 12 (10%) harbored the African plasmid.

Among 104 isolates with the *tetM* determinant, 96.2% (100/104) carried the Dutch type; the remaining 4 carried the American-type.

The β-lactamase plasmid was present more frequently in TRNG isolates than in non-TRNG isolates (47.1% [49/104] vs. 30.9% [71/230]; p < 0.01; Table 2). Forty nine PPNG/TRNG isolates exhibited two patterns that combined β-lactamase and *tetM* containing plasmids: Asian type β-lactamase expressing isolates always harbored the Dutch *tetM* type; the combination of African type β-lactamase and American type *tetM* was rarely identified in PPNG/TRNG (3 isolates) in Nanjing (Table 2).

Genetic characteristics of *N. gonorrhoeae* isolates with increased MIC to ceftriaxone
Fifteen (4.5%) isolates had elevated MICs (≥0.125 mg/L) to ceftriaxone. A second determination on the 15 isolates confirmed the MICs. According to recent CLSI breakpoint criteria [37], these isolates would be classified as “susceptible” but treatment failures have occurred when infected strains possessed MICs around 0.125 mg/L [6,10,11]. We examined these 15 isolates for genetic mutations in *penA*, *mtrR*, *penB*, *ponA* and *pilQ* genes (Table 3).

Four PBP2 amino acid sequence patterns were identified; PBP2 allele XVIII was the predominant type (n = 11), followed by XIII (n = 2) and XII (n = 1). A new pattern containing five mutations (345D insertion, A501V, F504L, A510V and A516G) was designated PBP2 allele XI, according to the previously used nomenclature of PBP2 alleles in *N. gonorrhoeae* [12,15,46-49]; none of these is a mosaic allele. However, 12 isolates (allele XVIII and XLI) possessed an A501T substitution in PBP2, and 2 isolates (allele XIII) had an A501V substitution.

Fourteen of fifteen isolates contained a single nucleotide (A) deletion in the 13 bp inverted repeat motif located between −10 and −35 sequence in the *mtrR* promoter. Five isolates (including two with ceftriaxone MICs = 0.25 mg/L) also had a G45D or A39T substitution in the DNA-binding motif of MtrR, and one isolate possessed a single amino acid replacement (A39T). We did not identify the recently described C-to-T mutation 120 bp upstream of the *mtrC* start codon, termed *mtrC*210 [51].

All isolates possessed *penB* resistance determinants with substitutions at both G120 and A121 in loop 3 of the PorB1b outer membrane porin; these included G120K/A121D (n = 7), G120K/A121G (n = 6), G120N/A121D (n = 1) and G120K/A121N (n = 1).

Finally, the L421P substitution in PBP1 caused by a single nucleotide mutation (T to C) in the *ponA* gene was detected in all isolates; we saw no alternations in the *pilQ* gene.

The fifteen isolates that harbored 14 different *porB* sequences and 12 *tpbp* sequences were assigned to 15 different NG-MAST STs: ST8737, ST3289, ST2186, ST3746, ST2461, ST5061 and 9 new STs. Eleven isolates with the PBP2 allele, XVIII, the most common PBP2, were resolved into 11 separate NG-MAST STs (Table 3).

**Discussion**
Our study reported high-levels of resistance to previously recommended therapeutic agents for *N. gonorrhoeae* of

### Table 1 In vitro antimicrobial susceptibility of *Neisseria gonorrhoeae*: clinical isolates (n = 334)

| Antimicrobial breakpoints (susceptible/resistant [mg/L]) | No. (%) | MIC (mg/L) |
|----------------------------------------------------------|---------|------------|
|                                                          | Susceptible | Intermediate | Resistant | Range | MIC₉₀ | MIC₉₀ |
| Penicillin G (S ≤ 0.06/R ≥ 2)                            | 0         | 108 (32.3) | 226 (67.7) | 0.125 to >8 | 2 | >8 |
| Tetracycline (S ≤ 0.25/R ≥ 2)                            | 2 (0.6)   | 5 (1.5)    | 327 (97.9) | 0.25 to >16 | 8 | >16 |
| Ciprofloxacin (S ≤ 0.06/R ≥ 1)                           | 0         | 4 (1.2)    | 330 (98.8) | ≤0.25 to >8 | >8 | >8 |
| Spectinomycin (S ≤ 32/R ≥ 128)                           | 334 (100) | 0          | 0          | ≤0.125 to ≤0.25 | 0.03 | 0.06 |

| Ceftriaxone (S ≤ 0.25)                                    | 334 (100) | -          | -          | 0.004 to 0.25 | 0.03 | 0.06 |

*Antimicrobial breakpoints that distinguish susceptible from resistant gonococcal isolates (CLSI Document M07-A9 [M100-S22]) [35]. MIC: minimum inhibitory concentration.*

### Table 2 Distribution of β-lactamase-encoding and *tetM*-encoding plasmids: *Neisseria gonorrhoeae* clinical isolates (n = 334)

| Type of *tetM*-encoding plasmid | Type of β-lactamase producing plasmid | β-lactamase negative |
|----------------------------------|---------------------------------------|----------------------|
| Dutch                            | Asian/New Zealand                      | 46                   |
|                                  | African/Nimes                          | 0                    |
|                                  |                                       | 54                   |
| American                         | 0                                     | 3                    |
|                                  | 1                                     |
| *tetM* negative                  | 62                                    | 9                    |
|                                  | 159                                   |                      |
isolates from men with urethritis in Nanjing (2011–12): ciprofloxacin (98.8%); tetracycline (97.9%) and penicillin (67.7%). Rates of resistance have remained unchanged compared with that of 2006, the last year of a six yearly sequential measurement [39]. Similar patterns of resistance have also been noted from other cities in southern China; Shanghai (ciprofloxacin 98.7%, tetracycline 73.6%, penicillin 98.1% [exact time period for isolates collection not available]) [52], Shenzhen (ciprofloxacin 98.7%, tetracycline 98.1%, penicillin 99.0% in 2008) [50], Hainan (ciprofloxacin 96.1%, tetracycline 73.6%, penicillin 98.1%) [53] and other western pacific and south-eastern Asian regions including Vietnam, Korea, India, Pakistan and Bhutan [28,31,55-57]. The contribution of plasmid mediated resistance was similar in Nanjing in the period 2011–12 compared to 2006 [39], but during this interval declines in the proportion of PPNG have been observed in Korea [57], Canada [58], Latin America and the Caribbean countries [59]. Because treatment of gonorrhoea with ciprofloxacin, tetracycline and penicillin has long been discontinued in Nanjing [30,39], persistence of resistant phenotypes may be explained by the stability of mechanisms that promote resistance or the presence of unidentified selection pressures due to use of antibiotics for other reasons including the common practice of self-medication with antibiotics. In our study, 33% of men with gonococcal urethritis reported self-administration of antibiotics in the 30 days prior to their clinic visit (unpublished data).

It is encouraging to note that the percentage of gonococci isolates with decreased susceptibility to ceftriaxone (MIC ≥0.125 mg/L) declined significantly from 9.1% (18/198) in 2006 [39] to 4.5% (15/334) in 2011–12 (p = 0.04); a one dilution decrease of the modal MIC for ceftriaxone was also observed (0.06 mg/L in 2006 to 0.03 mg/L in 2011–12) (Figure 1). In Europe [32,60-63], Australia [64], Africa [65-67], the western hemisphere [33,58,59,68-70] and the South-East Asia Region [31], MICs to ceftriaxone have risen during this period. Nonetheless, it is of concern that the distribution of spectinomycin MICs shifted upward in Nanjing during the same interval, between 2006 and 2011–12 (Figure 2) [39]. In 2006, an MIC = 32 mg/L to spectinomycin was observed (0.06 mg/L in 2006 to 0.03 mg/L in 2011–12) (Figure 1). In Europe [32,60-63], Australia [64], Africa [65-67], the western hemisphere [33,58,59,68-70] and the South-East Asia Region [31], MICs to ceftriaxone may, in part, result from the greater use of spectinomycin in the Nanjing STD clinic. Ninety-eight percent of gonococcal urethritis cases in men were prescribed spectinomycin as recently as 2011–12 (p < 0.01), coinciding with a significant decrease in the percentage of strains whose MICs ≤8 mg/L (p < 0.01). Opposing trends in resistance of gonococcal isolates to ceftriaxone and spectinomycin may, in part, result from the greater use of spectinomycin in the Nanjing STD clinic.

| Isolate no. | Ceftriaxone MICs (mg/L) | Antimicrobial characteristics | NG-MAST STs | PBP2 allele | Polymorphisms in: |
|------------|------------------------|-----------------------------|-------------|-------------|-------------------|
|            |                        | porB | tcpB | STs | MtrR | PorB1b | PBP1 | PIIQ |
| NJ-1       | 0.25                   | CMRNG, CipR | 5658 | 111 | 9530 | XVIII | −57A del, A39T | G120K, A121D | L421P | wt |
| NJ-2       | 0.25                   | CMRNG, CipR | 5175 | 328 | 8737 | XVIII | −57A del, A39T | G120K, A121D | L421P | wt |
| NJ-3       | 0.125                  | PPNG, CipR | 5659 | 107 | 9531 | XVIII | −57A del | G120K, A121G | L421P | wt |
| NJ-4       | 0.125                  | PP/TRNG, CipR | 1053 | 186 | 3289 | XVIII | −57A del | G120K, A121D | L421P | wt |
| NJ-5       | 0.125                  | PPNG, CipR | 1854 | 33  | 9532 | XII | −57A del | G120N, A121D | L421P | wt |
| NJ-6       | 0.125                  | PP/TRNG, CipR | 543  | 294 | 9533 | XVIII | A39T | G120K, A121G | L421P | wt |
| NJ-7       | 0.125                  | CMRNG, CipR | 5660 | 186 | 9534 | XVIII | −57A del | G120K, A121G | L421P | wt |
| NJ-8       | 0.125                  | CMRNG, CipR | 505  | 135 | 2186 | XVIII | −57A del | G120K, A121D | L421P | wt |
| NJ-9       | 0.125                  | CMRNG, CipR | 1285 | 4  | 9535 | XIII | −57A del, G45D | G120K, A121D | L421P | wt |
| NJ-10      | 0.125                  | TRNG, CipR | 4   | 831 | 3746 | XIII | −57A del | G120K, A121D | L421P | wt |
| NJ-11      | 0.125                  | CMRNG, CipR | 3530 | 4  | 9536 | XVIII | −57A del | G120K, A121G | L421P | wt |
| NJ-12      | 0.125                  | CMRNG, CipR | 1198 | 156 | 2461 | XVIII | −57A del, A39T | G120K, A121G | L421P | wt |
| NJ-13      | 0.125                  | CMRNG, CipR | 5661 | 4 | 5061 | XVIII | −57A del, G45D | G120K, A121N | L421P | wt |
| NJ-14      | 0.125                  | CMRNG, CipR | 2978 | 1058 | 9537 | XII | −57A del | G120K, A121D | L421P | wt |
| NJ-15      | 0.125                  | TRNG, CipR | 543  | 438 | 9538 | XVIII | −57A del | G120K, A121G | L421P | wt |

*New NG-MAST STs detected in this study.
**A new PB2 allele previously not identified was named XLI according to previously used Nomenclature.

| wt, wild type. | Isolates exhibiting resistance to ciprofloxacin (MIC ≥1 mg/L). | It is encouraging to note that the percentage of gonococci isolates with decreased susceptibility to ceftriaxone (MIC ≥0.125 mg/L) declined significantly from 9.1% (18/198) in 2006 [39] to 4.5% (15/334) in 2011–12 (p = 0.04); a one dilution decrease of the modal MIC for ceftriaxone was also observed (0.06 mg/L in 2006 to 0.03 mg/L in 2011–12) (Figure 1). In Europe [32,60-63], Australia [64], Africa [65-67], the western hemisphere [33,58,59,68-70] and the South-East Asia Region [31], MICs to ceftriaxone have risen during this period. Nonetheless, it is of concern that the distribution of spectinomycin MICs shifted upward in Nanjing during the same interval, between 2006 and 2011–12 (Figure 2) [39]. In 2006, an MIC = 32 mg/L to spectinomycin was observed in 1.0% of strains, rising to 18.3% in 2011–12 (p < 0.01), coinciding with a significant decrease in the percentage of strains whose MICs ≤8 mg/L (p < 0.01). Opposing trends in resistance of gonococcal isolates to ceftriaxone and spectinomycin may, in part, result from the greater use of spectinomycin in the Nanjing STD clinic. Ninety-eight percent of gonococcal urethritis cases in men were prescribed spectinomycin as recently as 2011–12 (p < 0.01), coinciding with a significant decrease in the percentage of strains whose MICs ≤8 mg/L (p < 0.01). Opposing trends in resistance of gonococcal isolates to ceftriaxone and spectinomycin may, in part, result from the greater use of spectinomycin in the Nanjing STD clinic.
tale” of clinical failure when it is used as primary treatment of gonorrhea [72].

Plasmids carried by PPNG and TRNG isolates have changed over time in Nanjing [39]. The highly active TEM $\beta$-lactamase gene is carried by a family of plasmids in *N. gonorrhoeae*. Since 1976, at least eight different plasmids have been identified from geographically distinct locations [73]. The $\beta$-lactamase gene has been found on Asian-, African- and Toronto-type plasmids carried by epidemic strains of *N. gonorrhoeae* [74], even while new types such as the Johannesburg and Australian plasmids are being discovered [75,76]. We did not differentiate the Nîmes plasmid from the African-type or the New Zealand plasmid from the Asian-type, owing to the identical sizes of the PCR products but we would have identified the novel Johannesburg plasmid identified by the 458 bp PCR products using the primer pair designed for the African-type plasmid. Using a simple multiplex PCR method [43], we detected either Asian/New Zealand type (n = 108) or African/Nîmes type (n = 12) plasmids in all penicillinase-positive isolates. The Asian/New Zealand type plasmid dominated, while the newly emerging African/Nîmes type, which was absent in Nanjing isolates of 2006, and were epidemic in the United Kingdom (UK) and West Africa.
men may have been cured of infection with isolates under estimated AMR [87-89]. Simultaneously, infected sites (there were only two MSMs in our study) may have increased resistance of their gonococcal isolates. Exclusion of isolates from asymptomatic men and from extragential creased resistance of their gonococcal isolates. Exclusion of isolates from asymptomatic men and from extragential sites (there were only two MSMs in our study) may have underestimated AMR [87-89]. Simultaneously, infected men may have been cured of infection with isolates sensitive to the antibiotics that they had used earlier and therefore not seen in the clinic. This may have also led to an overabundance of more resistant N. gonorrhoeae. 

Conclusions
This study confirmed that ceftriaxone and spectino-
ymycin remain effective empiric first-line therapy for gon-orrhea in Nanjing. However, years of discontinued use of formerly recommended antimicrobial agents did not restore the sensitivities of gonococcal strains to cipro-
floxacin, penicillin or tetracycline. Changes and multiple representative types of resistance plasmid profiles high-
light frequent influx and exchange of N. gonorrhoeae strains. Reduced ceftriaxone susceptibility was found in 4.5% of gonococcal isolates and alterations in penA, mtrR, and penB genes were important determinants of resistance. Sustained surveillance of gonococcal pheno-
typic and genotypic AMR is an important element in the control of gonococcal infection.

Abbreviations
AMR: Antimicrobial resistance; PPNG: Penicillinase-producing N. gonorrhoeae; TRNG: Tetracycline-resistant N. gonorrhoeae; MIC: Minimum inhibitory concentration; NG-MAST: Neisseria gonorrhoeae multi-antigen sequence typing; ST: Sequence type; STI: Sexually transmitted infection; STD: Sexually transmitted diseases; ESC: Extended-spectrum cephalosporins; WHO: World Health Organization; CLSI: Clinical and Laboratory Standards Institute; PBP: Penicillin-binding protein.

Competing interests
The authors declare no competing interests.

Authors’ contributions
SL completed the gene determinants sequencing, NG-MAST, assisted with the antimicrobial susceptibility testing and prepared the manuscript. XHS directed the project, supervised the bacterial isolates collection and consulted on the manuscript preparation. WJL and FXJ carried out the antimicrobial susceptibility testing and the tetM and β-lactamase gene producing plasmids identification. BXW and PAR consulted on the project and manuscript preparation. All authors read and approved the final manuscript.

Acknowledgements
This work was supported in part by NIH grant AI084048.

Author details
1 STD Clinic, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China. 2 Department of Dermatology, Anhui Provincial Hospital, Hefei 230001, China. 3 Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01602, USA.

Received: 4 October 2014 Accepted: 7 November 2014
Published online: 27 November 2014

References
1. National Health and Family Planning Commissiom of the People's Republic of China. 2013 Annual National Report Of Notifiable Infectious Diseases [http://www.nhfpc.gov.cn/jkj/s3578/201404/f81a87a2fe3f453a996777a7d9d81ddolc]
2. World Health Organization (WHO) Department of Reproductive Health and Research: Global action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae. Geneva: WHO Press; 2012 [http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf]
1. Warner DM, Shafer WM, Jerse AE: Derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump is associated with mutations G542S, P551S and P551L in penicillin-binding protein 2. J Antimicrob Chemother 2009, 63:1615–1618.

2. Warner DM, Shafer WM, Jerse AE: Clinically relevant mutations that derepress the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol 2008, 70:462–478.

3. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM: Resistance to antimicrobial hydrophobic agents is mediated by the mtrRDED efflux system. Microbiology 1995, 141(Pt 3):611–622.

4. Gill MJ, Simjee S, Al-Hattawi K, Robertson BD, Easmon CS, Ison CA: Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Chemother 1998, 42:2799–2803.

5. Ison CA, Husey C, Sankar KN, Evans J, Alexander S: Gonorrhoea treatment failure to cefixime and azithromycin in England, 2010. Euro Surveill 2011, 16(14).

6. Unemo M, Nicholas RA: Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhoea. Future Microbiol 2012, 7:1401–1422.

7. Barry PM, Klausner JD: The use of cefalteparin for gonorrhoea: the impending problem of resistance. Expert Opin Pharmacother 2009, 10:555–577.

8. Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, Lowndes CM, GRASP collaborative group: Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. Lancet Infect Dis 2013, 13:762–768.

9. Kirkaldy RD, Kidd S, Weinstock HS, Papp JR, Bolan GA: Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006–June 2012. Sex Transm Infect 2013, 89(4):iv8–iv10.

10. World Health Organization: Antimicrobial Resistance Global Report on Surveillance. Geneva: WHO Press; 2014 [http://apps.who.int/iris/bitstream/10665/10565/1/WHO_HSE_PED_AIP_2014.2_eng.pdf].

11. Tapsall J: Antimicrobial Resistance in Neisseria Gonorrhoeae. Stockholm: ECDC; 2012.

12. Centers for Disease Control and Prevention (CDC): Ceftriaxone-Resistant Neisseria Gonorrhoeae Public Health Response Plan, CDC 2012 [http://www.cdc.gov/std/treatment/Ceph-R-ResponsePlanJuly30-2012.pdf].

13. European Centre for Disease Prevention and Control (ECDC): Cefixime-resistant Neisseria gonorrhoeae in Europe. Stockholm: ECDC; 2012.

14. National Center for STD Control, China CDC: Brief report of Chinese Gonococcal Surveillance. [http://www.nscdc.org/show.asp?id=967].

15. Sherrard J, Barlow D: Gonorrhoea in men: clinical and diagnostic aspects. Gmj/tourn Med 1996, 72:402–426.

16. CLSI: Neisseria gonorrhoeae. In Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012:100–102.

17. Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C: Simple method for detecting penicillinase-producing Neisseria gonorrhoeae and Staphylococcus aureus. Br J Vener Dis 1981, 57:141–142.

18. Gorwitz RJ, Nakashima AK, Moran JS, Knapp JS: Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae—United States, 1988–1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ 1993, 42:29–39.
56. Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M, Dillon JA, Trecker MA, Thakur SD, Gonococcal Antimicrobial Surveillance Programme in Europe 2011. J Antimicrob Chemother 2013, 68:1016–1023.
57. Lee SG, Lee H, Jeong SH, Yong D, Chung GT, Lee YS, Chong Y, Lee K: Reduced susceptibility to ceftriaxone. J Antimicrob Chemother 2013, 68:1053–1057.
58. Yang Y, WL ZC, Gu W: The role of penicillin-binding protein 2 (PBP2) in the cephalosporin susceptibility of Neisseria gonorrhoeae and the need for consensus in naming of PBP2. J Antimicrob Chemother 2013, 68:1267–1270.
59. Lewis DA, Sinrutth C, Muller EE, Golparian D, Gumedze L, Fick D, de Wet J, Maseko V, Coetsee J, Unemo M: Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013, 68:1271–1274.
60. Hottes TS, Lester RT, Hoang LM, McKay R, Imperial M, Gilbert M, Patrick D, Wong T, Martin I, Ogilvie G: Cefixime and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis 2013, 40:46–51.
61. Centers for Disease Control and Prevention: Cefixime susceptibility among Neisseria gonorrhoeae isolates–United States, 2000–2010. MMWR Morb Mortal Wkly Rep 2011, 60:875–877.
62. Unemo M, Golparian D, Skogen V, Olsen AO, Moi H, Syversen G, Hjelmevoll SO: Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway. Antimicrob Agents Chemother 2013, 57:1057–1061.
63. Boslego JW, Tramont EC, Takafuki ET, Dinsehie BM, Mitchell BS, Small JW, Khan WN, Stein DC: Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987, 317:272–278.
64. Phillips I: Beta-lactamase-producing, penicillin-resistant gonococcus. Lancet 1976, 2:656–657.
65. Dillon JA, Yeung KH: Beta-lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev 1989, 2:325–353.
66. Fayeowoo SA, Muller EE, Gumedze L, Lewis DA: Plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in South Africa: prevalence, detection and typing using a novel molecular assay. Sex Transm Dis 2011, 38:329–333.
67. Trembali E, Buckley C, Lawrence A, Laaha M, Whiley D, GRAND Study Investigators: Characterisation of a novel Neisseria gonorrhoeae penicillinase-producing plasmid isolated in Australia in 2012. Antimicrob Agents Chemother 2014, 58:4984–4985.
68. Shimuta K, Unemo M, Nakayama S, Morita-Ishihara T, Dorin M, Kawahata T, Ohnishi M, Antibiotic-Resistant Gonorrhea Study Group: Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftiraxone resistance. Antimicrob Agents Chemother 2013, 57:5225–5232.
69. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P: Phenotypic and genotypic properties of Neisseria gonorrhoeae isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines. Eur J Clin Microbiol Infect Dis 2012, 31:1181–1186.
70. Golparian D, Hellmark B, Fredlund H, Unemo M: Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased
susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010, 86:454–460.

81. Gose S, Nguyen D, Lowenberg D, Samuel M, Bauer H, Pandori M. Neisseria gonorrhoeae and extended-spectrum cephalosporins in California: surveillance and molecular detection of mosaic penA. BMC Infect Dis 2013, 13:570.

82. Tomberg J, Unemo M, Davies C, Nicholas RA. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 2010, 49:8062–8070.

83. Centers for Disease Control Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines. 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012, 61:590–594.

84. Bignell C, Fitzgerald M, Guideline Development Group, British Association for Sexual Health and HIV UK. UK national guideline for the management of gonorrhoea in adults. 2011. Int J STD AIDS 2011, 22:541–547.

85. Bignell C, Unemo M, European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013, 24:85–92.

86. Yuan LF, Yin YP, Dai XQ, Pearlme RV, Xiang Z, Unemo M, Chen XS. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011, 38:764–768.

87. Read PJ, Limnios EA, McNulty A, Whiley D, Lahra MM. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. Sex Health 2013, 10:460–462.

88. YC M, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013, 68:1445–1447.

89. Deguchi T, Yasuda M, Itô S. Management of pharyngeal gonorrhoea is crucial to prevent the emergence and spread of antibiotic-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother 2012, 56:4039–4040. author reply 4041–4032.